How safe and effective is subcutaneous immunotherapy (SCIT), particularly single allergen regimens, for treating allergic rhinoconjunctivitis and asthma?
Background: Allergen immunotherapy is usually recommended for patients whose allergic rhinoconjunctivitis and asthma symptoms cannot be controlled by environmental and pharmaceutical means or who do not adhere to medication regimens. SCIT suppresses or eliminates symptoms by administering increasing doses of an allergen-containing extract. This study focuses on SCIT formulations that are available in the United States.
Explore this issue:March 2014
Study design: Database review of studies published between 1967 and May 2012.
Setting: MEDLINE, Embase, LILACS, Cochrane Central Register of Controlled Trials, public registries of clinical trials, and scientific information packets requested from relevant pharmaceutical companies.| | | Next → | Single Page